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Despite several advances, the underlying mechanism 
of complexity of breast cancer progression still re-
mains elusive. In addition to the genetic predisposition, 
several growth factor receptors including insulin 
growth factor receptor (IGF), platelet derived growth 
factor (PDGF) and vascular endothelial growth factor 
(VEGF) relaying proliferative signals are accountable 
for disease progression. Epidermal growth factor re-
ceptors (EGFRs, or commonly known as ErbBs), 
members of the receptor tyrosine kinase family 
(RTKs), play a central role in tumor growth, progres-
sion and metastatic disease. Typically, agonist depend-
ent activation of EGFR results in receptor phosphory-
lation, homo- and/or heterodimerization and modula-
tion of signaling pathways leading to cell proliferation, 
survival and metastasis. Targeting one or multiple 
steps in EGFR-mediated tumor progression may serve 
as a better approach in drug therapies. Unlike EGFRs, 
G-protein coupled somatostatin receptors (SSTRs) 
have been recognized as negative regulators of breast 
tumors. The activation of SSTRs modulates down-
stream signaling responsible for tumor growth and 
consequent cytostatic or cytotoxic effects on tumor 
proliferation. SSTR subtypes are well characterized to 
form homo-and/or heterodimers within the same fam-
ily as well as with other GPCRs. Clinically, the chi-
meric molecule targeting both SSTR5 and dopamine 
receptors (specifically dopamine receptor 2) is in use 
for the treatment of pituitary tumors. This review de-
scribes the interplay between SSTRs and EGFR and 
the potential role of such cross talk in attenuation of 
EGFR-mediated signaling pathways involved in tu-
morigenesis. Furthermore, recent findings supporting 
the role of SSTR in EGFR-mediated signaling in tu-
mor biology are discussed in detail. 
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Introduction 
 
Breast cancer is a complex heterogeneous form of can-
cer affecting 1 in 9 women worldwide. Each year, 
more than a million new cases of breast cancer and 
~400,000 deaths are globally reported. While 90-95% 
are sporadic only 5-10% of all breast cancer cases are 
hereditary (Rosen et al. 2003). Breast cancer progres-
sion is often manifested by excessive cell proliferation, 
genetic mutations, angiogenesis and metastasis. More 
than 20-30% of the total hereditary breast tumors are 
due to inherited genetic mutations in breast cancer 1-
susceptibility genes (BRCA1) and BRCA2 (Easton et 
al. 1995, Rosen et al. 2003, Wooster et al. 1995). The 
amplification of the cmyc gene is observed in 20-30% 
of breast tumors and linked with aggressive metastatic 
tumors of high grade (Deming et al. 2000). In normal 
breast tissue, p53 and phosphatase and tensin homolog 
(PTEN) function as tumor suppressor genes; however, 
mutations in p53 and loss of PTEN are associated with 
a high risk of breast cancer (Tsutsui et al. 2005). Cur-
rent studies are focused on defining and identifying 
prognostic biomarkers including BRCA1 and BRCA2 
genetic mutations, estrogen/progesterone (E/P) status 
and expression of p53/PTEN. The identification of 
such new biomarkers and their implication in progno-
sis and diagnosis has enhanced the understanding of 
the etiology of breast tumors and the application of 
individualized targeted therapies against tumor pro-
gression while reducing death rates (Weigel & 
Dowsett 2010). Despite such advances, classical mark-
ers including E, P and epidermal growth factor recep-
tors (ErbBs) are routinely assessed for diagnostic and 
pathological examinations in breast cancer. So far, an 
extensive amount of research has been directed to the 
factors responsible for tumor progression, including 
EGFR; however, the potential significance of certain 
receptor proteins such as somatostatin receptors 
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(SSTRs), which are responsible for tumor suppression, 
has not been studied in detail. More importantly, the 
physiological significance and pharmacological inter-
action between such receptor proteins remains to be 
elucidated. 
 The role of ErbB1 (commonly known as 
EGFR) in human malignancies including neck, head, 
colon and breast has been investigated extensively and 
thus remains the major target for anti-neoplastic drug 
discovery (Nicholson et al. 2001, Yarden 2001, 
Zimmermann et al. 2006). Interestingly, the EGFR and 
ErbB2 subtypes are over-expressed in > 30% of tu-
mors with poor survival (Abd El-Rehim et al. 2004, 
Bo et al. 2008). Hyperactivity due to autocrine secre-
tion in the ErbB network leads to over-production of 
ligands and receptors by the breast tumor cells. EGFR-
mediated breast tumor progression is manifested by (i) 
over-expression, (ii) EGFR phosphorylation and (iii) 
homo and/or heterodimerization, preferentially with 
ErbB2, leading to aberrant downstream signaling path-
ways (Bo et al. 2008, Earp et al. 1995, Kallergi et al. 
2008, Kraus et al. 1987, Martin & Philippe 2008, 
Olayioye et al. 2000, Ullrich et al. 1984, Yarden 
2001). Numerous therapies including tyrosine kinase 
inhibitors (e.g., Lapatinib, Gefitinib and erlotinib) and 
monoclonal antibodies ( e.g. trastuzumab, cetuximab) 
are clinically available, however, targeting EGFR 
alone has been deemed insufficient as a means of con-
trolling the progression of breast tumors (Alvarez et al. 
2010). 
In retrospect, the anti-proliferative role of 
somatostatin (SST), a multifunctional endogenous 
regulatory neuropeptide has been employed for the 
treatment of tumors of different origins (Ben-Shlomo 
& Melmed 2008, Buscail et al. 1995, 2002). The bio-
logical effects of SST are mediated by five membrane 
bound SSTR1-5 belonging to the G-protein coupled 
receptor family (Patel 1999). SSTRs are also known to 
regulate secretion of most, if not all, endocrine/
exocrine hormones and growth factors. SSTRs activate 
various downstream targets and negatively regulate 
cell proliferation (Bousquet et al. 2004, Florio et al. 
1999, 2000, Hagemeister & Sheridan 2008, Lahlou et 
al. 2004). The activation of SSTRs promotes homo- 
and/or heterodimerization within the same family and 
with other GPCRs and results in the modulation of 
downstream signaling cascades more efficiently com-
pared to the native receptors (Grant et al. 2004, Grant 
& Kumar 2009, Pfeiffer et al. 2002, Rocheville et al. 
2000a, b, Saveanu et al. 2002, Somvanshi et al. 2011). 
SSTRs have been clinically proven effective in sup-
pressing pituitary and pancreatic tumor growth (Ben-
Shlomo & Melmed 2008, Bousquet et al. 2004, Jaquet 
et al. 2005). A recent study from the authors' labora-
tory showed a receptor-specific colocalization between 
SSTRs and ErbBs in human breast cancer cells (Watt 
& Kumar 2006). These observations indicate the possi-
bility of a potential functional interaction between 
SSTRs and ErbBs in breast cancer. Nevertheless, the 
mechanistic role of SSTRs in the modulation of EGFR 
homo- and/or heterodimerization, phosphorylation and 
consequent inhibition of downstream signaling path-
ways remains elusive. The main emphasis of this re-
view is to define the mechanisms that might be associ-
ated with the interaction of SSTR and ErbB subtypes 
and their pronounced impact in the modulation of sig-
naling pathways which are critical in tumor progres-
sion and inhibition. 
 
Epidermal Growth Factor Receptors 
Epidermal growth factor (EGF) regulates normal as 
well as neoplastic cell growth. EGF mediates its bio-
logical effects via ErbBs. Ullrich et al. (1984) first 
identified EGFR as the cell surface receptor in malig-
nant cells and characterized it using molecular cloning 
techniques. The ErbB family is comprised of four 
transmembrane receptors (EGFR-4) that belong to the 
receptor tyrosine kinase (RTK) family (Carpenter et al. 
1978, Yarden 2001). ErbBs are commonly comprised 
of three components: (i) the ligand-binding extracellu-
lar (EC) domain, (ii) the hydrophobic transmembrane 
region and, (iii) the intracellular cytoplasmic domain 
that is linked with the former and contains the tyrosine 
kinase domain (Harris et al. 2003, Savage et al. 1972). 
The extracellular domain is comprised of four subdo-
mains designated as large domains (L1 and L2) and 
cysteine rich domains (C1 and C2) (Bajaj et al. 1987, 
Garrett et al. 2002, Ogiso et al. 2002). The intracellu-
lar domain of ErbBs consists of a highly conserved 
tyrosine kinase and C-terminal domain, involved in 
phosphorylation and transmission of downstream sig-
naling (Garrett et al. 2002, Ogiso et al. 2002). There is 
a 53% structural homology within all the ErbB sub-
types, not accounting for the differences in the tyrosine 
kinase domains (Jorissen et al. 2003). EGFR upon 
binding to EGF interacts with other ErbBs to activate 
the tyrosine kinase residues. However, ErbB2 is the 
only subtype which does not bind to any ligands and 
depends on other ErbBs, preferentially EGFR and 
ErbB3, for its activation and functionality. ErbB3 
uniquely lacks inherent receptor kinase activity and 
relies on other ligand-activated ErbBs for its function 
(Guy et al. 1994). The expression of ErbB4, in general, 
is relatively less than of other ErbB subtypes. ErbB4, 
although having a tyrosine kinase domain, requires 
cleavage by membrane proteases to activate the intra-
cellular tyrosine and its translocation to the cell surface 
(Rio et al. 2000). 
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The ligands for ErbBs are classified into three 
major groups depending on the receptor binding speci-
ficity. The first class consists of EGF and EGF-like 
binding ligands, tumor growth factor-α (TGF-α) and 
amphiregulin (AR) that specifically bind to EGFR 
(Gullick 2001, Suo et al. 2002, Yarden 2001). The sec-
ond class is composed of betacellulin (BCT), heparin 
binding-EGF and epiregulin that bind to EGFR and 
ErbB3. The third is the neuregulins (NRGs) family that 
is further sub grouped into NRG1 and NRG2 that bind 
to ErbB3 and ErbB4 whereas NRG3 and NRG4 bind 
only to ErbB4 (Yarden 2001). Of the four receptors, 
ErbB2 is the only receptor subtype that does not bind 
to any known ligand and relies on other ligand acti-
vated ErbBs for its physiological functions (Suo et al. 
2002). 
 Prior to ligand binding, EGFR exists as a dor-
mant monomer within the cell membrane. Receptor 
dimerization leads to conformational changes and ex-
posure of the dimerization loop (Gadella & Jovin 
1995). These alterations bring two EGFR molecules in 
close proximity allowing receptor dimerization, pro-
vided there is a 1:1 ligand receptor complex. Binding 
of the two EGF molecules to EGFR stabilizes this 
complex formation (Lemmon et al. 1997). Binding of 
EGF to EGFR not only promotes homodimerization 
but also heterodimerization with other ErbBs (Earp et 
al. 1995). 
 
EGFR and Breast Cancer  
ErbBs are expressed in tissues of epithelial, mesenchy-
mal and neuronal origin and involved in embryonic 
development through adulthood. Preponderance of 
data from transgenic and knockout models has indi-
cated the role of EGFR in the development and normal 
functioning of tissues, most importantly in the brain 
and mammary gland (Alroy & Yarden 1997, Chryso-
gelos & Dickson 1994, Gospodarowicz 1981, Herbst 
2004). 
 EGF and its cognate receptors play an impor-
tant role in the normal development of the mammary 
gland. However, an imbalance in the regular cellular 
process of growth, repair and programmed cell death 
of the mammary gland leads to tumor formation. Aber-
rant functioning of EGFR is implicated in numerous 
human diseases including Alzheimer’s, cardiac dys-
function, psoriasis and skin lesions as well as psycho-
logical disorders including schizophrenia (Chaudhury 
et al. 2003, Hahn et al. 2006, King et al. 1990, Suzuki 
et al. 2002). However, the most studied role of EGFR 
is in tumorigenesis. EGFR and ErbB2 are the most 
studied prototype of ErbBs associated with the pro-
gression of breast cancer (Olayioye et al. 2000). A to-
tal of 40-50% of breast carcinomas express ErbBs 
(Abd El-Rehim et al. 2004, Normanno et al. 2006). 
Breast tumors expressing EGFR and ErbB2 are associ-
ated with poor clinical outcome (DiGiovanna et al. 
2005, Toi et al. 1994). ErbB2 is likely to have a higher 
oncogenic transforming ability in comparison to 
EGFR. Overexpression, gene amplification and recep-
tor mutations have been demonstrated in different tu-
mor types. In addition, co-expression of ErbB subtypes 
enhances the transforming ability of breast cancer 
cells. An elegant study by DiGiovanna et al. (2005) 
reported that 15% of the 807 invasive breast tumors 
expressed EGFR and that the majority of these tumors 
(87%) co-expressed ErbB2 establishing a striking cor-
relation between the expression of these two factors in 
breast cancer patients. Consistent with these observa-
tions, studies have also revealed that tumors with co-
expression of EGFR/ErbB2/ErbB3 or ErbB2/ErbB3  
have a more aggressive phenotype than tumors co-
expressing ErbB3/ErbB4 (Abd El-Rehim et al. 2004). 
 The overexpression of EGFR and ErbB2 is 
often accompanied by elevated production of ligands 
such as EGF and transforming growth factor-β (TGF-
β) as well as hyperactivated downstream  signaling 
cascades (Normanno et al. 2006, Pilichowska et al. 
1987). Immunohistochemical analysis of breast carci-
nomas revealed that more than 65% of cases were 
positive for EGF and TGF-a. In aggressive breast can-
cer, EGF not only enhances mitogen activated protein 
kinase (MAPK) phosphorylation but is also associated 
with sustained and prolonged basal ERK1/2 expression 
(Thottassery et al. 2004). Kallergi et al. (2008) demon-
strated that circulating tumor cells in blood samples 
from breast cancer patients expressed phosphorylated 
EGFR and ErbB2 in the early stages of the disease as 
well as in metastatic tumors. Additionally, these cells 
also displayed high levels of phosphatidylinositol-3-
kinase (PI3K)/AKT phosphorylation. Any mutations in 
PI3K and AKT are associated with loss of PTEN and 
over-expression of ErbB2 (Kallergi et al. 2007a, b). 
Recently, nuclear translocation of EGFR was shown to 
exert a potential role in breast tumor cells associated 
with enhanced cell proliferation and with the induction 
of cyclin D1, a positive regulator of cell proliferation 
(Lo et al. 2005, Wang et al. 2010). 
 
Molecular Signaling of EGFR  
EGF binding to its cognate receptor induces dimeriza-
tion, phosphorylation and internalization of the EGFR 
that triggers a network of intricate signaling. Among 
various signaling cascades, four major pathways that 
are regulated by EGFR include Janus kinase (JAK), 
signal transducers and activators of transcription 
(STAT), phospholipase C (PLC) and protein kinase C 
(PKC) pathways (Alroy & Yarden 1997, Citri & 
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Yarden 2006, Darnell et al. 1994, Jorissen et al. 2003, 
Katz et al. 2007). Of the multitude of signaling path-
ways, all ErbBs activate the Ras-MAPK upon ligand 
binding (Figure 1). EGFR targets several members of 
the MAPK family including extracellular regulated 
receptor kinases (ERK) ERK1/2, ERK5, janus kinases 
(JNK) and p38. Specifically, ERK1/2 is the most stud-
ied and well characterized pathway activated by 
growth factor receptors and associated with cell prolif-
eration (Katz et al. 2007). MAPKs are serine/threonine 
kinases that orchestrate key cellular functions includ-
ing cell growth, differentiation and proliferation. 
MAPK pathways are activated either by direct recruit-
ment of the Src homology 2 (SH2) domain linked 
growth factor receptor-bound protein 2 (Grb2) or indi-
rectly by the phosphotyrosine-binding (PTB) domain. 
Grb2 then recruits son of sevenless (SOS), a nucleotide 
exchange factor further activating Ras, upon exchange 
of guanosine diphosphate (GDP) to guanosine triphos-
phate (GTP). Activated Ras, in turn, phosphorylates 
Raf and results in activation of downstream kinases 
including MAP kinase kinases (MEK1/2). MEK1/2 
subsequently phosphorylates ERK1/2 leading to the 
nuclear translocation of activated ERK where it initi-
ates transcription of various genes including the speci-
ficity protein 1 (SP1), E2F, E twenty-six (ETS)-like 
transcription factor 1 (ElK-1) and activator protein 1 
(AP-1). Gene transcription ultimately promotes cell 
growth including proliferation, differentiation, migra-
tion, invasion and anti-apoptosis. Recent studies have 
described a new isoform of ERK, ERK5 that is linked 
to tumorigenesis and associated with cell proliferation. 
The in vivo animal studies support a critical role of 
ERK5 in tumor growth due to the vasculogenesis and 
blood vessel homeostasis. Most importantly, tumor 
cells displaying high expression of ErbB2 also exhibit 
elevated basal expression of ERK5 (Montero et al. 
2009). 
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Figure 1. Overview of the EGFR signaling pathway. Binding of EGF to EGFR leads to homo- and/or heterodimerization of 
EGFR, phosphorylation and activation of MAPK (ERK/p38) and cell survival (PI3K/AKT) pathways. These pathways conse-
quently induce cell proliferation, invasion, and migration. 
 In addition to MAPK pathways, the second 
most oncogenic pathway and focus of attention in tu-
mor biology has been the PI3K/AKT (cell survival) 
pathway (Yap et al. 2008). This pathway plays a cen-
tral role in cell proliferation, metabolism, growth and 
migration to overcome the deleterious and stressful 
microenvironment in non-tumor cells (Vivanco & 
Sawyers 2002). Inappropriate PI3K signaling is typi-
cally associated with EGFR mediated tumor growth 
and failure in EGFR inhibition is linked with sustained 
PI3K signaling. There are three classes of PI3Ks, of 
which PI3K of class IA family are clearly activated by 
growth factors including EGFR (Courtney et al. 2010, 
Kallergi et al. 2007a, Liang et al. 2006, Nicholson & 
Anderson 2002). Upon activation of EGFR, the p85 
catalytic subunit binds to the receptor tyrosine residues 
and translocates PI3K to the plasma membrane 
(Vivanco & Sawyers 2002). The membrane transloca-
tion of PI3K phosphorylates its substrate phosphatidy-
linositol (4,5)-bisphosphate (PIP2) to phosphatidy-
linositol (4,5)-trisphosphate (PIP3) and activates AKT 
via binding to its upstream activator, phosphoinositide-
dependent kinase 1 (PDK1). AKT is the major down-
stream target of PI3K and upon activation leads to en-
hanced cell growth and survival of tumors. Studies 
have shown that EGFR regulates the activity of cyclin 
CD1, which induces cyclin dependent kinases that pro-
mote cell cycle progression. Activation of AKT down-
regulates p27Kip1, an inhibitor of cyclin dependent 
kinases and regulates the cell cycle arrest (Vivanco & 
Sawyers 2002). Several genetic abnormalities are 
marked by the hyperactivation of PI3K/AKT signaling 
including the loss of PTEN, a tumor suppressor gene 
that dephosphorylates PIP3 to PIP2 hence shutting of 
the PI3K pathway (Courtney et al. 2010, Kallergi et al. 
2007a, Liang et al. 2006, Nicholson & Anderson 
2002). 
 JAK-STAT pathway is also involved in EGFR 
mediated carcinogenesis. JAK belongs to the tyrosine 
kinases family that activates STATs (Darnell et al. 
1994). EGFR can mediate signaling via STATS by 
different mechanisms, i.e, direct activation of STATs 
as well as by src-mediated EGFR signaling (Quesnelle 
et al. 2007). There are seven known members of the 
STAT family: STAT1-4, STAT5a, STAT5b and 
STAT6. Upon activation by cytokines or growth fac-
tors, STATs undergo phosphorylation following asso-
ciation with JAK. Homo- or heterodimerization of 
STATs is a pre-requisite prior to their nuclear translo-
cation and induction of gene transcription. TGF-α or 
EGF binding to EGFR is associated with activation of 
STAT-1, 3 and 5, in particular (Olayioye et al. 1999). 
 
EGFR Directed Therapy in Breast Cancer 
 EGFR and ErbB2 over-expression, phosphory-
lation and heterodimerization are integral in tumor pro-
gression and therefore serve as important prognostic 
factors for the development of therapeutic targets 
(Normanno et al. 2003). The main approach to control 
tumor growth is targeting ErbBs and its signal trans-
duction leading to inhibition of gene transcription. 
Two strategies are commonly used for the treatment of 
ErbBs positive breast cancer; monoclonal antibodies 
that block the membrane receptor upon binding to the 
EC domain and small molecule tyrosine kinase inhibi-
tors (TKIs) that block the tyrosine kinase activity and 
modulate downstream signaling pathways (Ciardiello  
& Tortora 2001). 
 The monoclonal antibody trastuzumab is the 
first line therapy for metastatic breast cancer and has 
been used clinically extensively (Goldenberg 1999). 
Trastuzumab binds to the EC domain of the ErbB2 
receptor and inhibits the receptor phosphorylation, 
thereby abrogating the tumor proliferation with better 
outcome in breast cancer patients (Bozionellou et al. 
2004). Randomized control trials have shown additive 
effects of trastuzumab with chemotherapy to reduce 
the recurrence of disease by 50% and mortality by 
>30%. An adjuvant therapy with paclitaxel (Taxol) in 
60-80% of breast cancer patients showed a promising 
outcome. Trastuzumab, in an adjunct therapy with 
other anti-tumor agents such as aromatase inhibitor 
(anastrazole) have proven beneficial in ER/ErbB posi-
tive breast tumors (Kaufman et al. 2009). Unlike tras-
tuzumab, which binds to EC domain of ErbB2, Pertu-
zumab, a newly discovered monoclonal antibody, pre-
vents ErbB2 homo- and heterodimerization with other 
ErbBs, which is an important phenomenon seen in ag-
gressive breast cancer tumors with shorter survival 
rates (Kristjansdottir & Dizon 2010). Cetuximab, a 
chimeric human-mouse monoclonal antibody also 
binds to EGFR (Harding & Burtness 2005). Further-
more, the complex of cetuximab-EGFR internalizes to 
cause defective downstream signaling and inhibition of 
cell proliferation leading to decreased invasiveness and 
metastasis (Harding & Burtness 2005).  
 In addition, several TKIs including gefitinib, 
eroltinib and lapatinib are approved for clinical use 
(Alvarez et al. 2010). Gefitinib and erlotinib are spe-
cific EGFR inhibitors that bind to EGFR extracellu-
larly and terminate the downstream signaling, pre-
dominantly interfering with the ERK1/2 and PI3K/
AKT signaling pathways (Campos 2008). Gefitinib is 
a potent inhibitor of cell proliferation in tumors over-
expressing EGFR. In phase I trials, gefitinib was well-
tolerated with limited toxicities, mainly dermal and 
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gastrointestinal (Herbst et al. 2002; Nakagawa et al. 
2003). In patients with tamoxifen resistant breast tu-
mors, gefitinib showed anti-proliferative activity 
(Baselga et al. 2005). Lapatinib, a reversible TKI, is 
clinically used in breast tumors expressing both EGFR 
and ErbB2. Interestingly, lapatinib binds to the mu-
tated or truncated forms of ErbB2 and exhibits an anti-
tumor effect (Bouchalova et al. 2010). A newly dis-
covered TKI, neratinib is an irreversible inhibitor of 
EGFR that has the ability to permanently abolish the 
intracellular kinase activity of the receptor until a new 
receptor is synthesized and exhibits prolonged anti-
tumor activity (Bose & Ozer 2009). 
 
Somatostatin and Somatostatin Receptors 
The role of SST in the negative regulation of normal 
and tumor cell growth as well as the modulation of 
growth factors and hormone mediated cell prolifera-
tion has emerged as a potential therapeutic approach 
for tumor treatment (Pyronnet et al. 2008, Susini & 
Buscail 2006). The diverse biological effects of SST 
are mediated through the interaction with the five spe-
cific receptors SSTR1-5. SSTRs were initially identi-
fied in rodent pituitary cells as high affinity cell sur-
face receptors (Schonbrunn & Tashjian 1978). The 
existence of more than one SSTR subtype was later 
proposed due to differential binding to SST-14 and 
SST-28 (Mandarino et al. 1981, Srikant & Patel 
1981). Based on their molecular cloning and binding 
properties, SSTRs were classified into two sub-
families; somatotropin release-inhibiting factor (SRIF)
-1 and SRIF-2 (Patel 1998). The SRIF-1 class was 
comprised of receptor subtypes sensitive to a specific 
ligand named OCT whereas receptors insensitive to 
this ligand constituted the SRIF-2 class (Reisine & 
Bell 1995, Tran et al. 1985). SSTRs belong to the hep-
tahelical transmembrane GPCRs family and are high 
affinity cell surface receptors (Schonbrunn & Tashjian 
1978). The sequence of human SSTRs was elucidated 
using molecular cloning techniques long after the 
identification of high-affinity plasma membrane SSTR 
binding sites (Yamada et al. 1992, 1993). SSTR sub-
types have been cloned and are pharmacologically 
characterized in various species including humans 
(Bruno et al. 1992, Kluxen et al. 1992, O'Carroll et al. 
1992). SSTR1 and SSTR2 were first cloned from hu-
man islets followed by cloning of SSTR3, SSTR4 and 
SSTR5 in human as well as rat tissues (Yamada et al. 
1992, 1993). Except SSTR2, the genes encoding 
SSTRs are intronless (Patel 1999). SSTR2 gene ex-
presses 2 splice variants; SSTR2A and SSTR2B, 
which differ in the number of amino acids in the C-
terminus. The size of SSTRs ranges from 356-391 
amino acid residues in length and exhibits 39-57% 
structural homology (Patel 1998, Reisine & Bell 
1995). The transmembrane domains of SSTRs display 
greater sequence homology than the extracellular N-
terminal and intracellular C-terminal domains (Patel 
1998). The pharmacological and physiological proper-
ties of SSTR in target tissues are subtype-specific. All 
SSTRs bind to SST-14 and SST-28 with nanomolar 
affinities. The pharmacological profiles of receptors to 
ligand binding revealed that SSTR1-4 bind to SST-14 
while SSTR5 binds to SST-28 with greater affinity 
(Patel 1998, 1999). 
 
Homo and/or Heterodimerization of SSTRs 
The concept that GPCR exist and function in mono-
meric entities has recently been challenged. The pres-
ence of multiple SSTR subtypes in the same cells in 
different tissues suggests the potential for dimerization 
between different SSTRs. Homo and/or heterodimeri-
zation of GPCRs within the same family has been well 
documented (Baragli et al. 2007, Grant et al. 2004, 
Heldin 1995, Jaquet et al. 2005, Jordan et al. 2001, 
Rocheville et al. 2000a). Such protein-protein interac-
tions are potential targets for new therapeutic agents. 
Rocheville et al. (2000b) were the first to report evi-
dence of physical interactions between SSTRs in trans-
fected cells. This study described that SSTR5 exists as 
a monomer in basal conditions and formed stable 
dimers upon SST treatment in a concentration depend-
ent manner. Patel et al. (2002) demonstrated an agonist 
dependent heterodimerization between SSTR1 and 
SSTR5, whereas SSTR5 formed homo and het-
erodimers. Unlike SSTR5, SSTR1 remained as a 
monomer, irrespective of the agonist stimulation. Fur-
thermore, the heterodimerization between SSTR1 and 
SSTR5 was subtype specific and was promoted by 
SSTR5 activation alone (Patel et al. 2002). The swap-
ping of SSTR5 C-tail with the C-tail of SSTR1 abro-
gated the agonist mediated homodimerization and in-
ternalization of SSTR5. Conversely, replacing the 
SSTR1 with the SSTR5 C-tail,   surprisingly, resulted 
in the chimeric receptor mimicking heterodimerization 
and internalization of SSTR5 upon agonist stimulation. 
Grant et al. (2004) described that SSTR2 exists as pre-
formed dimers, which dissociate upon agonist treat-
ment prior to internalization. The same authors in a 
separate study also reported that SSTR2 activation se-
lectively promotes heterodimerization between 
SSTR2/5 whereas activation of SSTR5 alone or with 
SSTR2 failed to produce such heterodimerization. Fur-
thermore, heterodimerization between SSTR2/5 modu-
lates the signaling properties and was shown to have 
an enhanced anti-proliferative effect. War et al. (2011) 
demonstrated that SSTR3 exists as a pre-formed 
homodimer in the basal state whereas agonist treat-
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ment decreases dimer formation. Additionally, C-tail 
deficient SSTR3 displayed homodimerization similar 
to wt-SSTR3 (War et al. 2011). Similarly, SSTR4 ex-
ists as a dimer in monotransfected cells, however, 
upon deletion of the C-tail, the receptor lost the ability 
to dimerize and displayed impaired internalization 
(Somvanshi et al. 2009). Moreover, SSTR4 exhibited 
receptor specific heterodimerization with SSTR5 but 
not with SSTR1 (Somvanshi et al. 2009). These stud-
ies established the critical role of the C-tail in receptor 
dimerization and internalization and suggested that 
activation of one protomer is sufficient to promote re-
ceptor dimerization. Furthermore, SSTR2/3 het-
erodimers displayed high binding affinity to SST-14 
and SSTR2 specific agonist and resistance to agonist-
induced desensitization. Interestingly, SSTR2/3 het-
erodimers were identified as new receptors, albeit with 
similar pharmacological properties as SSTR2 but with 
the loss of SSTR3-like properties (Pfeiffer et al. 2001). 
 Heterodimerization of SSTRs within the same 
family and with other related GPCRs is a well-
established notion. SSTR2 functionally interact with µ-
opioid receptor in HEK-293 cells (Pfeiffer et al. 2002). 
Furthermore, heterodimerization between SSTR5 and 
dopamine receptor subtype 2 (D2R) and SSTR2/D2R 
opened an opportunity for the development of chimeric 
molecules targeting SSTR5/D2R that have been suc-
cessfully applied in the treatment of pituitary tumors 
(acromegaly) (Baragli et al. 2007, Jaquet et al. 2005, 
Saveanu et al. 2002). Recent studies showed that syn-
ergistic activation strengthened the pre-existing SSTR5 
and β-adrenergic heterodimers whereas activation of 
individual receptor subtypes leads to the dissociation 
of the heteromeric complex (Somvanshi et al. 2011). 
The heterodimerization of SSTRs has been shown to 
enhance the signaling properties and such functional 
consequences may have potential therapeutic implica-
tions in different pathological states. 
 
Molecular Signaling of SSTRs 
Ligand binding to SSTRs initiates complex signal 
transduction pathways (Figure 2). Agonist mediated 
activation of SSTRs leads to conformational changes 
in the receptor prior to coupling with the G-proteins 
comprised of a trimeric complex of three tightly bound 
subunits (α, β and γ). Upon activation, G-proteins con-
vert GDP to GTP by nucleotide exchange and conse-
quently relay downstream signals via dissociation of 
the α subunit from the βγ complex (Pierce et al. 2002). 
Adenylyl cyclase (AC) was among the first identified 
enzyme effectors regulated by GPCRs, including 
SSTRs (Patel et al. 1994). All SSTR subtypes bind to 
pertussis toxin (PTX) sensitive G-proteins that are Gi/o 
type and negatively regulate AC to inhibit cAMP for-
mation, which further downregulates the protein kinase 
A (PKA) pathway (Meyerhof 1998). The inhibitory 
effect of SSTRs on the cAMP/PKA pathway has been 
demonstrated in human pituitary adenomas, rat cortex 
and hippocampus, pancreatic islets as well as ovine 
retina, in a receptor specific manner (Meyerhof 1998, 
Patel 1999). SSTRs alter cGMP in a receptor and tis-
sue dependent manner, by modulating the activity of 
guanylyl cyclase, which also regulates nitric oxide me-
diated oxidative stress (Lahlou et al. 2004). Earlier 
studies on rat pancreatic islets, human pituitary adeno-
mas and various other cell types have also demon-
strated that SSTRs modulate ion channels (Ca2+ and 
K+) as well as phospholipase A (PLA) and phospholi-
pase C (PLC) pathways (Cervia & Bagnoli 2007, 
Csaba & Dournaud 2001, Lahlou et al. 2004, Reisine 
& Bell 1995). Additionally, SSTRs, via Gao2, regulate 
high-voltage gated Ca2+ channels and also inhibit intra-
cellular Ca2+ entry in human pituitary adenomas, car-
diac fibroblasts and cortical astrocytes as well as in rat 
sympathetic neurons, hippocampus and pancreatic 
cells (Ikeda & Schofield 1989; Kleuss et al. 1991; Zhu 
& Yakel 1997). Concerning the specificity of the re-
ceptor subtype, the involvement of SSTR2 has been 
studied in modulation of cAMP and Ca2+ whereas lim-
ited information is available on the roles of other sub-
types in this regard. Furthermore, SST has also been 
suggested to activate conductance of different K+ 
channels via SSTR4, leading to hyperpolarization of 
the cell membrane in human and rat brain regions as 
well as pituitary and pancreatic cells (de Weille et al. 
1989). The effects of SST on the Na+/H+ pump have 
been studied in rat hepatocytes as well as breast cancer 
cells of different origins and are mainly mediated via 
SSTR2 and SSTR5. 
 
SSTRs and Breast Cancer 
 
SST and SSTRs are highly expressed by breast cancer 
cells and autopsied breast tissue. SSTl immunoreactiv-
ity has been demonstrated in approximately 30% of 
breast tumor tissues as well as in most breast cancer 
cell lines (Albérini et al. 2000, Kumar et al. 2005, 
Reubi 1990, Weckbecker et al. 1994). As discussed 
above, there are direct and indirect mechanisms for the 
SST effects on breast tumor cells. The direct effect of 
SST or its analogs is exerted by binding to SSTRs, 
resulting in inhibition of cell proliferation and/or in-
duction of apoptosis. Studies have demonstrated that 
15-66% of primary breast tumors are positive for 
SSTRs by binding analysis whereas 75% were posi-
tive when imaged in vivo using [111In-DTPA-DPhe1]
-octreotide scintigraphy (Prevost et al. 1994, Weck-
becker et al. 1994). Pfeiffer et al. (2002) demonstrated 
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that SSTR2 and SSTR5 were the predominant sub-
types expressed in these tumors. Several previous 
studies have also reported that SSTR2 is the most 
abundant SSTR subtype expressed in breast tumors 
(Evans et al. 1997, Kumar et al. 2005, Reubi et al. 
1990, Watt & Kumar 2006). In addition, SSTR2 ex-
pression has been found to be ubiquitous (Evans et al 
1997). Vikic-Topic et al. (1995) described that the 
SSTR2 transcript is predominantly expressed in all 
breast tissue samples, followed by SSTR1, SSTR3 and 
SSTR4. Moreover, SSTR1 was detected along with 
SSTR2 transcripts in 96% of breast tissues examined. 
Furthermore, the expression of mRNA and protein 
levels of all SSTR subtypes was shown in a cumula-
tive study of 98 ductal not otherwise specified (NOS) 
breast tumor cases (Kumar et al. 2005). Additionally, 
it was suggested that the SSTRs are variably distrib-
uted at the tumor site and adjacent tumor regions 
(Kumar et al. 2005). In contrast to observations by 
Vikic-Topic et al., the findings by Kumar et al. (2005) 
established the correlation of SSTRs with the tumor 
grade and the levels of ER and PR. SSTR1 and 4 were 
correlated with ER whereas SSTR2 was correlated 
with PR in addition to ER. 
 In the past few years, various SST analogs 
have been developed and used as anti-proliferative 
agents in the treatment of breast cancer. Unlike SST 
that has a short plasma half-life of 3 minutes, newly 
synthesized SST analogs have better efficacy, thera-
peutic index and are free from major side effects 
(Lamberts et al. 1991, Schally 1988). Setyono-Han et 
al. (1987) showed the inhibitory effects of Sandostatin 
(an analog of SST) on proliferation of MCF-7 cells in 
a concentration and time dependent manner. Interest-
ingly, Sandostatin had an antagonizing effect on estra-
diol and growth hormones in MCF-7 cells suggesting 
that SST and SST analogs directly act as potential anti
-proliferative agents on human breast cancer cells. 
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Figure 2. Schematic illustration of SSTR signaling. Activation of SSTRs by SST or receptor-specific agonists inhibits Ca2+ 
influx and hormonal secretions. SSTRs couple to Gi proteins and commonly inhibit cAMP. SSTRs modulate the MAPK and 
PI3K pathways in a receptor specific manner and result in inhibition of cell proliferation, survival and migration. 
Vapreotide, another SST analog, was evaluated and it 
was found that prolonged administration was well tol-
erated in cases of pre-treated metastatic patients, re-
sulting in diminished levels of IGF-1 during the entire 
length of the treatment (O'Byrne et al. 1999). Simi-
larly, Canobbio et al. (1995) indicated that the SST 
analog Lanreotide significantly suppressed the levels 
of IGF-1 in postmenopausal breast cancer patients 
previously untreated for the tumor. 
 Amongst all SST analogs, octeriotide (OCT) 
has been studied extensively for the treatment of dif-
ferent types of tumors. As an anti-hormonal drug, 
OCT has been used in combination with tamoxifen for 
the treatment of breast cancer as well as in DMBA- 
induced rat mammary carcinoma. OCT also effec-
tively increased the anti-neoplastic effect of ovariec-
tomy in these rat models (Weckbecker et al. 1994). 
Sharma et al. (1996) demonstrated that SST had a cy-
totoxic effect on MCF-7 cells in a receptor-specific 
manner. In this regard, it should be noted that SSTR3 
is the only receptor subtype that uniquely participates 
in the induction of apoptosis. Furthermore, OCT in-
duced apoptosis through activation of tumor suppres-
sor proteins, namely wild-type 53 and Bcl-2–
associated X protein (Bax) in MCF-7 cells, suggesting 
a potential antitumor role of SST analogs (Sharma & 
Srikant 1998). Paclitaxel, known for its excellent anti-
tumor activity lacks cell specificity. Huang et al. 
(2000) synthesized an OCT conjugated with paclitaxel 
that internalized into the cytoplasm of SSTR positive 
tumor cells and induced apoptosis in MCF-7 cells by 
promoting tubule formation, while retaining pacli-
taxel's biological properties. 
 
Cross-talk between ErbBs and SSTRs  
EGFR has been associated with cell proliferation, sur-
vival and transformation (Normanno et al. 2006). In 
pathological conditions such as breast cancer, ErbBs 
are highly expressed in higher grade and aggressive 
tumors. SSTRs are known to be negative regulators of 
cell proliferation and have been acknowledged for the 
treatment of various tumors (Bousquet et al. 2004, 
Cameron Smith et al. 2003, Patel 1990). Unlike 
ErbBs, SSTRs are well expressed in lower grade and 
less aggressive breast tumors. These observations sug-
gest an inverse relation between SSTR and ErbB sub-
types in breast cancer. Finding that activation of 
GPCRs leads to the phosphorylation of EGFR result-
ing in enhanced and diversified signaling established 
the first paradigm of inter-receptor crosstalk. Daub et 
al. (1996) were the first to describe the concept of 
EGFR transactivation by GPCRs in rat fibroblasts. 
There is compelling evidence that could substantiate 
the possible crosstalk between SSTRs and ErbBs. All 
SSTR and ErbB subtypes are extensively expressed in 
breast tissues and cell lines (Kumar et al. 2005, Rivera 
et al. 2005, Watt & Kumar 2006). SSTRs and ErbBs 
are co-expressed in breast cancer cells and display 
colocalization in a receptor, cell line and ER-
dependent manner.  SSTR subtypes are highly ex-
pressed in ER- cells, whereas these cells expressed 
relatively low levels of ErbBs in comparison to ER+ 
cells (Watt and Kumar 2006). SST also inhibits the 
effects of EGF in pancreatic tumors, indicating that 
activation of SSTR subtypes may impede ErbBs het-
erodimerization and diminish its tumor promoting ef-
fects (Liebow et al. 1986). In addition, SSTRs and 
ErbBs regulate the MAPK and PI3K/AKT pathway in 
a receptor specific manner; albeit, with opposite out-
comes on cell proliferation. 
 
SSTRs Modulate EGFR Functions 
SSTR1 and SSTR5 modulate EGFR heterodimeriza-
tion and tumor promoting downstream signaling in 
breast cancer as well as HEK-293 cells (Watt et al. 
2009, Kharmate et al. 2011a, b) (summarized in Fig-
ure 3). In breast cancer cells, agonist treatment re-
sulted in the dissociation of SSTR5/EGFR and the 
association of SSTR1/EGFR. The agonist dependent 
association/dissociation between SSTRs/EGFR conse-
quently led to the modulation of ERK1/2 phosphoryla-
tion. Watt et al. (2009) demonstrated that there is a 
synergistic activation of SSTR and EGFR upon treat-
ment with SST and EGF which delayed the phos-
phorylation of ERK1/2 in MCF-7 cells, suggesting a 
mechanism whereby SST can block EGF-induced pro-
liferation. These results further strengthen the concept 
that SSTRs and ErbBs functionally interact in cancer. 
 The concept that SSTR and ErbB receptors 
associate as heterodimers or possibly display ligand-
dependent dissociation of preformed heteromeric com-
plexes with significant changes in signaling molecules 
has enormous implications for receptor biology in can-
cer and in drug development. Kharmate et al. (2011a, 
b) demonstrated that the presence of SSTR1 or 5 al-
tered EGFR membrane expression, phosphorylation 
and heterodimerization of EGFR/ErbB2. EGFR het-
erodimerization with ErbB2 and receptor phosphoryla-
tion are critical steps in stimulating and sustaining the 
downstream cell proliferating signals linked to tumor 
growth. The activation of SSTR 1 or 5 in transfected 
HEK-293 cells significantly diminished the membrane 
expression of EGFR, which was consistent with the 
observations in breast cancer cells. SSTR5 alone and 
in combination with SSTR1 partially blocked EGFR 
phosphorylation (Kharmate et al. 2011a, b). In com-
parison, SSTR1 monotransfected cells completely 
abolished EGFR phosphorylation. Furthermore, in wt-
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HEK-293 cells, while EGF enhanced the ERK1/2 
phosphorylation in a time dependent manner, SST 
alone or in combination with EGF showed comparable 
ERK1/2 phosphorylation. Interestingly, in SSTR1 or 
SSTR5 expressing cells, EGF induced ERK1/2 phos-
phorylation was significantly less, whereas upon con-
comitant treatment of SST and EGF, ERK1/2 phos-
phorylation was prolonged. Furthermore, activation of 
SSTR1 or 5 in mono- and/or cotransfected cells modu-
late EGF mediated ERK5 phosphorylation. Of note, 
SST displayed a much greater inhibitory effect on 
EGF mediated ERK1/2 and ERK5 phosphorylation in 
SSTR1/5 cotransfected cells. Similarly, SSTRs inhibit 
EGF mediated p38 phosphorylation in a receptor spe-
cific manner with pronounced inhibition in the pres-
ence of SSTR1 alone. Furthermore, these results were 
corroborated with the changes in the expression levels 
of p27kip1, an index of cell proliferation and PTP mem-
brane translocation. These results suggest that SSTR1 
and 5 specifically induced cytostatic rather than cyto-
toxic effects (Kharmate et al. 2011a, b). 
 PI3K/AKT cell survival pathways play an im-
portant role in tumor progression. Aggressive tumor 
growth is frequently associated with the loss of PTEN, 
a hyperactivated PI3K pathway and the failure of 
Trastuzumab therapy (Kallergi et al. 2008). Further-
more, the activation of SSTR1 or 5 lead to the inhibi-
tion of PI3K and AKT phosphorylation. Moreover, 
this inhibition was shown to be more pronounced in 
cells expressing SSTR1/5 indicating that SSTRs acti-
vation might play a role in response to Trastuzumab 
treatment in cancer. It is highly possible that the grad-
ual loss of SSTR subtypes as the tumor progresses 
might, in part, be responsible for the loss of Trastuzu-
mab responsiveness, being associated with enhanced 
PI3K and loss of PTEN. Kharmate et al. (2011a, b) 
demonstrated that cells expressing SSTR1, SSTR5 and 
SSTR1/5 promote the dissociation of the EGFR/
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Figure 3. SSTRs modulate EGF mediated signaling pathways. Activation of SSTRs inhibits the EGF-mediated EGFR homo- 
and/or heterodimerization, receptor phosphorylation as well as the MAPK and PI3K/AKT pathways, resulting in inhibition of 
cell proliferation.   
ErbB2 heteromeric complex. SSTR1 and SSTR5 
monotransfected cells exhibited SSTR1/EGFR or 
SSTR5/ EGFR heteromeric complex formation, result-
ing in the inhibition of EGFR phosphorylation. More 
importantly, SSTR1/5 cotransfected cells displayed 
SSTR5/EGFR heterodimerization whereas there was 
no SSTR1/EGFR complex formation. These observa-
tions show that the interference of SSTRs in the ErbB 
homo- and/or heterodimerization, the consequent inhi-
bition of EGFR phosphorylation and the regulation of 
EGF-mediated downstream signaling might serve as 
novel therapeutic targets in EGFR positive tumors. 
Most importantly, inhibition of EGFR using AG1478 
and knocking down EGFR in the presence of siRNA 
enhanced SSTR1 and SSTR5 mediated inhibition of 
cell proliferation via blocking of the tumor-promoting 
signaling cascades (Kallergi et al. 2008, Kharmate et 
al. 2011a, b) 
 
Conclusions and Future Directions 
 
Since ErbBs represent a prominent class of cell sur-
face proteins in tumors and are linked to the regulation 
of cell proliferation, interference in ErbB membrane 
functions and inhibition of tumor regulatory pathways 
may serve as an instrumental tool in drug design for 
the treatment of breast tumors. It is worth investigat-
ing whether SSTRs might be exploited therapeutically 
in combination with the inhibition of ErbBs for cancer 
treatment. This review underscores the unappreciated 
role of SSTRs that contribute to the inhibition of 
EGFR induced changes that may significantly advance 
our understanding of tumor progression, patient prog-
nosis and future drug development in EGFR positive 
breast tumors. 
 Given the wide spread distribution of EGFR in 
breast cancer and its effects, particularly in tumor cell 
proliferation, it is not surprising that its modulation 
has been the subject of great interest in tumor cell bi-
ology, including breast cancer. Unfortunately, the 
regulation of EGFR alone to date has been insufficient 
in controlling tumor growth. This review addresses a 
new dimension regarding the role of SSTR subtypes, 
which are also present in tumor cells and are potential 
targets to prevent tumor progression. Therapeutic ap-
plication of SSTR activation along with inhibition of 
EGFR may provide a new clinical approach in the 
treatment of breast cancer and lay the foundation for 
rational drug design, in order to maintain normal func-
tion of EGFR in tumor cells and spare cells from ag-
gressive proliferation. Nonetheless, SSTR subtypes 
appear to gain a prominent and unique role for thera-
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